Company Overview of Naurex, Inc.
Naurex, Inc., a clinical-stage company, develops novel therapies for psychiatry and neurology disorders for modulating the N-methyl-D-aspartic acid receptor (NMDAR). It offers novel chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The company provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. It offers its products for central nervous system conditions, including depression, anxiety disorders, cognitive disorders, pain, and addiction. Naurex, Inc. was founded in 2006 and is based in Evanston, Illinois.
1801 Maple Avenue
Evanston, IL 60201
Founded in 2006
Key Executives for Naurex, Inc.
Compensation as of Fiscal Year 2014.
Naurex, Inc. Key Developments
Naurex, Inc. Presents at Boston CEO Conference, Jun-05-2014 01:00 PM
Jun 2 14
Naurex, Inc. Presents at Boston CEO Conference, Jun-05-2014 01:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Derek A. Small, Director.
Naurex Inc. Reports Positive Phase 2b Results for Novel Antidepressant GLYX-13 and Advances NRX-1074 into Phase 2 Depression Study
May 6 14
Naurex Inc. announced that its two lead antidepressant programs achieved major milestones. Results from a Phase 2b clinical study of the company's lead compound, GLYX-13, showed that the drug was well-tolerated and that the rapid, robust, and sustained antidepressant effects observed in an earlier single-dose study were achieved and maintained with repeat dosing in subjects with difficult-to-treat depression. The company also reported that it initiated a Phase 2a study of its second-generation, orally active agent, NRX-1074, based on positive results from a recently completed Phase 1 study. NRX-1074 is in development for major depressive disorder (MDD). The Phase 2b GLYX-13 study was conducted across 25 U.S. sites that enrolled more than 400 subjects with MDD who had an inadequate response to their current antidepressants. The top-line results confirmed that repeat dosing of GLYX-13 resulted in the maintenance of marked and clinically meaningful antidepressant effects. No drug-related serious adverse events were reported, no subjects dropped out of the study due to drug-related adverse events, and there were no signs of the psychotomimetic side effects associated with NMDA receptor antagonists, such as ketamine. The objectives of the Phase 2a study now underway for NRX-1074 are to evaluate the safety and efficacy of a single dose of the compound administered to subjects with MDD. NRX-1074 is considerably more potent than GLYX-13 and, in preclinical studies, it has shown activity similar to GLYX-13, including signs of rapid onset and long-acting duration of antidepressant-like effect. The Phase 2a study of NRX-1074 follows successful completion of a randomized, placebo-controlled Phase 1 study in which NRX-1074 was well-tolerated by normal volunteers.
Naurex, Inc. Presents at UBS Global Healthcare Conference, May-19-2014 01:00 PM
Mar 19 14
Naurex, Inc. Presents at UBS Global Healthcare Conference, May-19-2014 01:00 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Norbert G. Riedel, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 1, 2014